The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: To determine whether short-time, real-time continuous glucose monitoring (RT-CGM) has long-term salutary glycemic effects in patients with type 2 diabetes who are not on prandial insulin. RESEARCH DESIGN AND METHODS: This was a randomized controlled trial of 100 adults with type 2 diabetes who were not on prandial insulin. This study compared the effects of 12 weeks of intermittent RT-CGM with self-monitoring of blood glucose (SMBG) on glycemic control over a 40-week follow-up period. Subjects received diabetes care from their regular provider without therapeutic intervention from the study team. RESULTS: There was a significant difference in A1C at the end of the 3-month active intervention that was sustained during the follow-up period. The mean, unadjusted A1C decreased by 1.0, 1.2, 0.8, and 0.8% in the RT-CGM group vs. 0.5, 0.5, 0.5, and 0.2% in the SMBG group at 12, 24, 38, and 52 weeks, respectively (P = 0.04). There was a significantly greater decline in A1C over the course of the study for the RT-CGM group than for the SMBG group, after adjusting for covariates (P < 0.0001). The subjects who used RT-CGM per protocol (≥48 days) improved the most (P < 0.0001). The improvement in the RT-CGM group occurred without a greater intensification of medication compared with those in the SMBG group. CONCLUSIONS: Subjects with type 2 diabetes not on prandial insulin who used RT-CGM intermittently for 12 weeks significantly improved glycemic control at 12 weeks and sustained the improvement without RT-CGM during the 40-week follow-up period, compared with those who used only SMBG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
The problem areas in diabetes scale: an evaluation of its clinical utility
Welch, G. W., Jacobson, A. M., & Polonsky, W. H. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.760 · Cited by 664 · cited 1×
“Diabetes-related distress was measured using the Problem Areas in Diabetes (PAID) questionnaire (17).”
MethodPickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 1×
“RT-CGM has been shown to improve glycemic control and/or reduce the frequency of hypoglycemic episodes in pediatric and adult patients with type 1 diabetes and in adult patients with type 2 diabetes taking prandial insulin (7–14), although age and frequency of sensor use affect the magnitude of the A1C reduction (15).”
BackgroundDeiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Polonsky, W. H., Hessler, D., Ruedy, K. J., & Beck, R. W. (2017) · Diabetes Care · doi:10.2337/dc17-0133 · Cited by 346
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307
Yapanis, M., James, S., Craig, M. E., O’Neal, D., & Ekinci, E. I. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac034 · Cited by 291
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Silbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
Ruedy, K. J., Parkin, C. G., Riddlesworth, T. D., & Graham, C. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817704445 · Cited by 225
Yaron, M., Roitman, E., Aharon-Hananel, G., Landau, Z., Ganz, T., Yanuv, I., Rozenberg, A., Karp, M., Ish-Shalom, M., Singer, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-0166 · Cited by 211
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
“Only about half of the 100 study participants used insulin to control hyperglycemia in this study (32).”
BackgroundHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis
Jancev, M., Vissers, T. A. C. M., Visseren, F. L. J., van Bon, A. C., Serné, E. H., DeVries, J. H., de Valk, H. W., & van Sloten, T. T. (2024) · Diabetologia · doi:10.1007/s00125-024-06107-6 · Cited by 191
“%) and studies including users of both insulin or oral agents [21, 26, 27, 30, 31] showed a mean change of −3.65 mmol/ mol (−0.33%; 95% CI −6.14, −1.15, p =0.004, I 2 =21”
BackgroundInfluentialPoolsup, N., Suksomboon, N., & Kyaw, A. M. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-39 · Cited by 179
“e, 26 weeks and 52 weeks, and presented the results in two separated papers [34,35].”
BackgroundPositioning time in range in diabetes management
Advani, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05027-0 · Cited by 170
Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetes Care · doi:10.2337/dci17-0043 · Cited by 135
Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P. (2024) · Diabetes Care · doi:10.2337/dc23-1520 · Cited by 124
Janapala, R. N., Jayaraj, J. S., Fathima, N., Kashif, T., Usman, N., Dasari, A., Jahan, N., & Sachmechi, I. (2019) · Cureus · doi:10.7759/cureus.5634 · Cited by 117
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00973-1 · Cited by 117
“In a further study, statistically significant reductions in HbA 1c achieved during a 12-week period of CGM use in people with T2DM not on intensive insulin therapy persisted for 52 weeks, despite a subsequent 40-week period using only Perspective SMBG 121 .”
Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
“5% in the rtCGM group compared to control over 12 weeks, and the glycemic benefits seen with rtCGM use persisted over 40 weeks.(36) Earlier systematic reviews and meta-analyses of CGM studies (including both rtCGM and professional CGM) suggested benefits of CGM in improving glycemic control, especially in insulin-trea…”
BackgroundMethodZahedani, A. D., McLaughlin, T., Veluvali, A., Aghaeepour, N., Hosseinian, A., Agarwal, S., Ruan, J., Tripathi, S., Woodward, M., Hashemi, N., et al. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00956-y · Cited by 96
“…control individuals showed notable TIR improvements, most signi fi cantly in healthy nondiabetics Time in range (TIR) refers to time spent in the following glucose ranges according to previous recommendations: 70 – 180 mg/dL for those with T2D, and 70 – 140 mg/dL for those without T2D 24,25,38 .”
Bergenstal, R. M., Mullen, D. M., Strock, E., Johnson, M. L., & Xi, M. X. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108106 · Cited by 87
The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes
Fonda, S. J., Graham, C., Munakata, J., Powers, J. M., Price, D., & Vigersky, R. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816628547 · Cited by 81
Self-citationAjjan, R. A., Jackson, N., & Thomson, S. A. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119827456 · Cited by 79
A virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits
Dixon, R. F., Zisser, H., Layne, J. E., Barleen, N. A., Miller, D. P., Moloney, D. P., Majithia, A. R., Gabbay, R. A., & Riff, J. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819888662 · Cited by 80
Price, D. A., Deng, Q., Kipnes, M., & Beck, S. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01086-y · Cited by 77
Dehghani Zahedani, A., Shariat Torbaghan, S., Rahili, S., Karlin, K., Scilley, D., Thakkar, R., Saberi, M., Hashemi, N., Perelman, D., Aghaeepour, N., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01081-3 · Cited by 62
Reviewing U.S. connected diabetes care: the newest member of the team
Levine, B. J., Close, K. L., & Gabbay, R. A. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0273 · Cited by 66
Moon, S. J., Kim, K., Lee, W. J., Lee, M. Y., Vigersky, R., & Park, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14852 · Cited by 69
Self-citationKühner, L., Semenyshyn, R., Hentschel, M., Neubrech, F., Tarín, C., & Giessen, H. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00488 · Cited by 68
Grace, T., & Salyer, J. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0212 · Cited by 64
“reported significant reductions in HbA1c with intermittent rtCGM use compared with BGM in a cohort of T2D adults treated with basal insulin or noninsulin therapy.(9) In a more recent study, investigators assessed the impact of using a novel telehealth technology/care model that Table 1.”
BackgroundMethodChoe, H. J., Rhee, E.-J., Won, J. C., Park, K. S., Lee, W.-Y., & Cho, Y. M. (2022) · Diabetes Care · doi:10.2337/dc22-0764 · Cited by 59
“(10), patients with T2D not on prandial insulin who used rtCGM intermittently for 12 weeks had improved HbA1c levels at 12 weeks, and this improvement was sustained during the 40 week followup without rtCGM, compared with the BGM group.”
Comprehensive Telehealth Model to Support Diabetes Self-Management
Aleppo, G., Gal, R. L., Raghinaru, D., Kruger, D., Beck, R. W., Bergenstal, R. M., Cushman, T., Hood, K. K., Johnson, M. L., McArthur, T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36876 · Cited by 42
Chesser, H., Srinivasan, S., Puckett, C., Gitelman, S. E., & Wong, J. C. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221139873 · Cited by 40
Lu, J., Ying, Z., Wang, P., Fu, M., Han, C., & Zhang, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15328 · Cited by 39
Layne, J. E., Jepson, L. H., Carite, A. M., Parkin, C. G., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0197 · Cited by 37
Continuous Glucose Monitoring in the Self-management of Type 2 Diabetes: A Paradigm Shift
Cox, D. J., Taylor, A. G., Moncrief, M., Diamond, A., Yancy, W. S., Hegde, S., & McCall, A. L. (2016) · Diabetes Care · doi:10.2337/dc15-2836 · Cited by 36
Kim, J. Y., Jin, S.-M., Sim, K. H., Kim, B.-Y., Cho, J. H., Moon, J. S., Lim, S., Kang, E. S., Park, C.-Y., Kim, S. G., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06152-1 · Cited by 36
Kong, S.-Y., & Cho, M.-K. (2024) · Healthcare · doi:10.3390/healthcare12050571 · Cited by 36
Aleppo, G., Hirsch, I. B., Parkin, C. G., McGill, J., Galindo, R., Kruger, D. F., Levy, C. J., Forlenza, G. P., Umpierrez, G. E., Grunberger, G., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0268 · Cited by 34
“Vigersky et al. 65 and Fonda et al. 66 in this randomized controlled trial, assessed the glycemic short-and long-term effects of intermittent rtCGM use in a cohort of 100 T2D adults treated with nonintensive therapies.”
BackgroundSharing patient-generated data with healthcare providers: findings from a 2019 national survey
Turner, K., Jo, A., Wei, G., Tabriz, A. A., Clary, A., & Jim, H. S. L. (2021) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa272 · Cited by 33
Rizos, E. C., Markozannes, G., Charitakis, N., Filis, P., Stoimeni, A. E., Nørgaard, K., Ntzani, E. E., & Tsilidis, K. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0599 · Cited by 21
Ribeiro, R. T., Andrade, R., Nascimento do Ó, D., Lopes, A. F., & Raposo, J. F. (2021) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.12.024 · Cited by 13
Rama Chandran, S., Rahman, N., Gandhi, M., Tan, N. C., Phoon, I. K. Y., Seah, D. E. J., Cheah, M. H., Sek, K., & Gardner, D. S.-L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111678 · Cited by 10
Practical Approaches to Continuous Glucose Monitoring in Primary Care: A UK-Based Consensus Opinion
Fernando, K., Alabraba, V., Welsh, J. B., Seidu, S., Strain, W. D., Bell, H. E., Davies, S., & Evans, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01706-x · Cited by 7
Ko, J., Moon, S., Ajjan, R. A., Lee, M. Y., Lee, H., Choi, B., Park, J., Lee, S., Kang, J., & Park, C. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16304 · Cited by 7
The Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes
Dabbagh, Z., McKee, M. D., Pirraglia, P. A., Clements, K. M., Liu, F., Amante, D. J., Shukla, P., & Gerber, B. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0536 · Cited by 7
Ssemmondo, E., Shah, N., Newham, M., Rigby, A., Buckland, R., Deshmukh, H., & Sathyapalan, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16116 · Cited by 6
Metadata
- Authors
- Vigersky, R. A., Fonda, S. J., Chellappa, M., Walker, M. S., & Ehrhardt, N. M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-12-09
- Volume
- 35
- Issue
- 1
- Pages
- 32-38
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2148723141
- Cited by
- 301
- References
- 35
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.